Observational studies reporting vitamin D and micronutrient insufficiencies during prolonged GLP-1RA use [94, 95, 101] suggest that nutritional monitoring may be warranted, although the magnitude and causal pathways remain to be clarified
Closing: The Clinical Bottom Line on Tesamorelin Tesamorelin stands apart from most peptides because it has a documented clinical evidence base, an FDA-approved indication, and a mechanism that is well understood at the molecular level
Examples of these medications include semaglutide, liraglutide, dulaglutide, and tirzepatide
Available at: Health.com
But, never shake the vial as it can disturb the constituents
On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002